Dactolisib (BEZ235) treatment inhibited mesothelioma cell growth by targeting mTOR (Zhou et al., 2014) and similarly, treatment with the mTOR inhibitor temsirolimus stopped MPM cell proliferation and was synergistic with cisplatin treatment in vitro and in vivo (Hoda et al., 2011). Here, MTOR is linked to mesothelioma.